HeartSciences and Fortitude Mining Announce Merger Agreement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 23 2026
0mins
HeartSciences Inc. saw a significant price increase of 50.85% as it crossed above the 5-day SMA during regular trading.
The company has entered into a merger agreement with Fortitude Mining Holdings, expected to close in the second half of 2026. This all-stock deal aims to create a leading Zcash mining venture under the ticker symbol TUDE, with HeartSciences CEO Andrew Simpson continuing to lead the healthcare business unit. The merger is anticipated to enhance competitiveness in the digital asset landscape, particularly in the mining sector.
This merger positions HeartSciences to leverage Fortitude's established mining operations, potentially increasing its market share and operational capabilities in the evolving digital asset market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HSCS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HSCS
Wall Street analysts forecast HSCS stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.880
Low
9.20
Averages
10.60
High
12.00
Current: 2.880
Low
9.20
Averages
10.60
High
12.00
No data
About HSCS
HeartSciences Inc. is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. The Company has libraries of artificial intelligence-enhanced electrocardiography (AI-ECG) algorithms and is developing AI-ECG solutions to be made available on either a hardware- agnostic cloud-based platform or its proprietary MyoVista wavECG device, to help identify cardiovascular disease in any care setting worldwide in a manner to suit different care providers. Its first product candidate for FDA clearance, the MyoVista wavECG, or the MyoVista, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction, which has traditionally only been available through the use of cardiac imaging. The MyoVista also provides conventional ECG information in the same test. It delivers AI-ECG algorithms using existing ECG devices across a hospital or health system.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
NeOnc Technologies Secures Drug Authorization, Market Focuses on Clinical Progress
- Clinical Authorization Breakthrough: NeOnc Technologies has received Investigational New Drug authorization from the Department of Health–Abu Dhabi for its NEO100 program, covering adult Phase 1 to Phase 2 studies and establishing a pathway for pediatric development in high-grade gliomas, significantly expanding its international clinical footprint and potentially accelerating parallel advancement of multiple development stages.
- Investor Focus on Data Release: The company expects to report NEO100-01 Phase 2a clinical data by the end of July 2026, and positive results could support discussions for additional regulatory pathways, enhancing market confidence in its product pipeline.
- Gene Editing Strategic Shift: The merger between Boundless Bio and Serapha Bio will create a company focused on gene-editing therapies for Alpha-1 Antitrypsin Deficiency, backed by approximately $230 million in financing, which is expected to support the completion of Phase 2 and initiation of Phase 3 for SERP-01, addressing a significant unmet medical need.
- Data Storage Agreement Surge: Backblaze has signed a five-year, multi-exabyte data storage agreement valued at approximately $335 million with CoreWeave, positioning itself as a key storage provider to meet the growing demand for AI computing capacity, thereby solidifying its strategic position within the rapidly evolving AI ecosystem.
See More
Fortitude Mining and HeartSciences to Merge in All-Stock Deal
- Merger Overview: Fortitude Mining Holdings and HeartSciences have agreed to merge in an all-stock transaction aimed at bringing a leading Zcash mining venture to public markets, with the deal expected to close in the second half of 2026 under the ticker symbol TUDE.
- Leadership Continuity: Following the merger, HeartSciences CEO Andrew Simpson will continue to lead the healthcare business unit, while Fortitude CEO Andrea Childs will head the combined leadership team, ensuring continuity in operations and strategic execution.
- Zcash Mining Performance: Fortitude began mining ZEC in 2019 and has scaled production to an annualized 157,000 ZEC as of May 31, 2026, averaging about 366 ZEC per day, with a trailing twelve-month return exceeding 1,000% for Zcash as of June 15, 2026, indicating strong market performance.
- Three-Pillar Operating Model: Fortitude's mining strategy integrates hardware procurement, infrastructure deployment, and R&D to support low-cost Zcash production, while also targeting high-margin opportunities in early-stage Proof-of-Work protocols to enhance long-term profitability.
See More
Fortitude and HeartSciences Announce Merger Agreement
- Merger Overview: Fortitude Mining Holdings and HeartSciences have signed a merger agreement expected to close in H2 2026, with the combined entity operating under the Fortitude brand on Nasdaq with the ticker "TUDE", marking a significant advancement in the digital asset mining sector.
- Market Positioning Advantage: Post-merger, Fortitude will become the first publicly traded venture mining platform focused on high-conviction early-stage Proof-of-Work opportunities, which is expected to enhance its competitiveness and market share in the digital asset landscape.
- Zcash Mining Strategy: Fortitude began mining Zcash in 2019, achieving an annualized production of 157,000 ZEC (approximately 366 ZEC/day), and through a vertically integrated mining strategy, it aims to lower costs and enhance operational leverage, solidifying its leadership in the privacy-preserving digital asset space.
- Shareholder Structure Changes: Following the merger, existing shareholder DCG is expected to own approximately 95% of the combined company, reflecting continued confidence in the business, while current HeartSciences CEO Andrew Simpson will continue to lead the healthcare business unit, ensuring continuity and stability in operations.
See More
HeartSciences Secures European Patent for AI-Driven ECG Technology
- Patent Grant: HeartSciences has been awarded European Patent No. EP4252651 by the EPO, covering ECG-based assessment of diastolic function, marking a significant expansion of its AI-ECG intellectual property portfolio and is expected to enhance its competitive edge in the market.
- Technological Innovation: The patented technology employs machine learning models to compute echocardiogram parameters indicative of diastolic function directly from ECG data and patient demographics, significantly improving the efficiency and accuracy of cardiac disease screening.
- Market Coverage: The patent took effect on April 29, 2026, providing coverage in 19 European countries, including Germany, France, and Italy, thereby reinforcing HeartSciences' strategic positioning in the European market.
- Intellectual Property Value: With over 45 granted patents, HeartSciences demonstrates a robust technological foundation and commercial advantage in the AI-ECG field, which is expected to support the company's future financial performance.
See More
HeartSciences Launches AI-ECG Algorithm Marketplace with FDA-Cleared Model
- Platform Update Released: HeartSciences announced the commercial release of MyoVista Insights™ version 1.3, introducing the AI-ECG Algorithm Marketplace, which allows integration of third-party algorithms, marking a significant advancement in ECG technology.
- FDA-Cleared Algorithm: The Bunkerhill Health ECG-EF model, which is FDA-cleared, enables clinicians to detect reduced left ventricular ejection fraction (LVEF ≤40%) from a routine 12-lead ECG, providing earlier identification of heart failure risk.
- Innovative Revenue Model: The marketplace offers a SaaS-based revenue model for AI-ECG developers, reducing the complexity of entering the clinical market, and is expected to attract more algorithm developers, driving sustainable revenue growth for the company.
- Medical Reimbursement Support: Assessments using AI-ECG algorithms are eligible for approximately $136 in Medicare reimbursement in 2026, and with the multi-billion-dollar market forecast for AI-ECG, HeartSciences is positioned for significant revenue growth in the future.
See More
HeartSciences Achieves Epic Toolbox Designation for MyoVista Insights
- Platform Certification: HeartSciences' MyoVista Insights™ platform has received Epic Toolbox designation, marking a significant milestone in the ECG management system sector and enhancing the company's competitiveness in the healthcare IT market.
- Integration Capabilities: The platform supports integration with hospital information systems and electronic health records (EHRs) using HL7v2 order and results workflows, single sign-on (SSO), and SMART on FHIR, ensuring clinicians can seamlessly access MyoVista Insights™ within existing workflows.
- Clinical Decision Support: MyoVista Insights™ is designed to enhance workflow efficiency and support clinical decision-making, which is expected to improve healthcare providers' workflows, thereby enhancing patient care quality and efficiency.
- Strategic Expansion: CEO Andrew Simpson stated that this certification is a crucial part of the company's interoperability strategy aimed at expanding access to MyoVista Insights™ across healthcare systems, driving future market growth.
See More
NeOnc Technologies Secures Drug Authorization, Market Focuses on Clinical Progress
- Clinical Authorization Breakthrough: NeOnc Technologies has received Investigational New Drug authorization from the Department of Health–Abu Dhabi for its NEO100 program, covering adult Phase 1 to Phase 2 studies and establishing a pathway for pediatric development in high-grade gliomas, significantly expanding its international clinical footprint and potentially accelerating parallel advancement of multiple development stages.
- Investor Focus on Data Release: The company expects to report NEO100-01 Phase 2a clinical data by the end of July 2026, and positive results could support discussions for additional regulatory pathways, enhancing market confidence in its product pipeline.
- Gene Editing Strategic Shift: The merger between Boundless Bio and Serapha Bio will create a company focused on gene-editing therapies for Alpha-1 Antitrypsin Deficiency, backed by approximately $230 million in financing, which is expected to support the completion of Phase 2 and initiation of Phase 3 for SERP-01, addressing a significant unmet medical need.
- Data Storage Agreement Surge: Backblaze has signed a five-year, multi-exabyte data storage agreement valued at approximately $335 million with CoreWeave, positioning itself as a key storage provider to meet the growing demand for AI computing capacity, thereby solidifying its strategic position within the rapidly evolving AI ecosystem.
See More
Fortitude Mining and HeartSciences to Merge in All-Stock Deal
- Merger Overview: Fortitude Mining Holdings and HeartSciences have agreed to merge in an all-stock transaction aimed at bringing a leading Zcash mining venture to public markets, with the deal expected to close in the second half of 2026 under the ticker symbol TUDE.
- Leadership Continuity: Following the merger, HeartSciences CEO Andrew Simpson will continue to lead the healthcare business unit, while Fortitude CEO Andrea Childs will head the combined leadership team, ensuring continuity in operations and strategic execution.
- Zcash Mining Performance: Fortitude began mining ZEC in 2019 and has scaled production to an annualized 157,000 ZEC as of May 31, 2026, averaging about 366 ZEC per day, with a trailing twelve-month return exceeding 1,000% for Zcash as of June 15, 2026, indicating strong market performance.
- Three-Pillar Operating Model: Fortitude's mining strategy integrates hardware procurement, infrastructure deployment, and R&D to support low-cost Zcash production, while also targeting high-margin opportunities in early-stage Proof-of-Work protocols to enhance long-term profitability.
See More
Fortitude and HeartSciences Announce Merger Agreement
- Merger Overview: Fortitude Mining Holdings and HeartSciences have signed a merger agreement expected to close in H2 2026, with the combined entity operating under the Fortitude brand on Nasdaq with the ticker "TUDE", marking a significant advancement in the digital asset mining sector.
- Market Positioning Advantage: Post-merger, Fortitude will become the first publicly traded venture mining platform focused on high-conviction early-stage Proof-of-Work opportunities, which is expected to enhance its competitiveness and market share in the digital asset landscape.
- Zcash Mining Strategy: Fortitude began mining Zcash in 2019, achieving an annualized production of 157,000 ZEC (approximately 366 ZEC/day), and through a vertically integrated mining strategy, it aims to lower costs and enhance operational leverage, solidifying its leadership in the privacy-preserving digital asset space.
- Shareholder Structure Changes: Following the merger, existing shareholder DCG is expected to own approximately 95% of the combined company, reflecting continued confidence in the business, while current HeartSciences CEO Andrew Simpson will continue to lead the healthcare business unit, ensuring continuity and stability in operations.
See More
HeartSciences Secures European Patent for AI-Driven ECG Technology
- Patent Grant: HeartSciences has been awarded European Patent No. EP4252651 by the EPO, covering ECG-based assessment of diastolic function, marking a significant expansion of its AI-ECG intellectual property portfolio and is expected to enhance its competitive edge in the market.
- Technological Innovation: The patented technology employs machine learning models to compute echocardiogram parameters indicative of diastolic function directly from ECG data and patient demographics, significantly improving the efficiency and accuracy of cardiac disease screening.
- Market Coverage: The patent took effect on April 29, 2026, providing coverage in 19 European countries, including Germany, France, and Italy, thereby reinforcing HeartSciences' strategic positioning in the European market.
- Intellectual Property Value: With over 45 granted patents, HeartSciences demonstrates a robust technological foundation and commercial advantage in the AI-ECG field, which is expected to support the company's future financial performance.
See More
HeartSciences Launches AI-ECG Algorithm Marketplace with FDA-Cleared Model
- Platform Update Released: HeartSciences announced the commercial release of MyoVista Insights™ version 1.3, introducing the AI-ECG Algorithm Marketplace, which allows integration of third-party algorithms, marking a significant advancement in ECG technology.
- FDA-Cleared Algorithm: The Bunkerhill Health ECG-EF model, which is FDA-cleared, enables clinicians to detect reduced left ventricular ejection fraction (LVEF ≤40%) from a routine 12-lead ECG, providing earlier identification of heart failure risk.
- Innovative Revenue Model: The marketplace offers a SaaS-based revenue model for AI-ECG developers, reducing the complexity of entering the clinical market, and is expected to attract more algorithm developers, driving sustainable revenue growth for the company.
- Medical Reimbursement Support: Assessments using AI-ECG algorithms are eligible for approximately $136 in Medicare reimbursement in 2026, and with the multi-billion-dollar market forecast for AI-ECG, HeartSciences is positioned for significant revenue growth in the future.
See More
HeartSciences Achieves Epic Toolbox Designation for MyoVista Insights
- Platform Certification: HeartSciences' MyoVista Insights™ platform has received Epic Toolbox designation, marking a significant milestone in the ECG management system sector and enhancing the company's competitiveness in the healthcare IT market.
- Integration Capabilities: The platform supports integration with hospital information systems and electronic health records (EHRs) using HL7v2 order and results workflows, single sign-on (SSO), and SMART on FHIR, ensuring clinicians can seamlessly access MyoVista Insights™ within existing workflows.
- Clinical Decision Support: MyoVista Insights™ is designed to enhance workflow efficiency and support clinical decision-making, which is expected to improve healthcare providers' workflows, thereby enhancing patient care quality and efficiency.
- Strategic Expansion: CEO Andrew Simpson stated that this certification is a crucial part of the company's interoperability strategy aimed at expanding access to MyoVista Insights™ across healthcare systems, driving future market growth.
See More
